Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Prostate-Specific Antigen (PSA) Testing Market Snapshot (2023 to 2033)

According to Future Market Insights research, during the projected period, the global prostate-specific antigen (PSA) testing market is expected to grow at a CAGR of 12.0%. The market value is projected to increase from US$ 6.3 Billion in 2023 to US$ 19.5 billion by 2033. The global prostate-specific antigen (PSA) testing market was valued at US$ 5.7 billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 11.1% in 2023.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 5.7 Billion
Market Value 2023 US$ 6.3 Billion
Market Value 2033 US$ 19.5 Billion
CAGR 2023 to 2033 12.0%
Share of Top 5 Countries 60.1%
Key Players The key players in the Prostate-Specific Antigen (PSA) Testing Market Are Xiamen Biotime Biotechnology Co., Ltd., HWTAi, OptiBio Co., Ltd, Jiangsu MicroDiag Biomedicine Technology Co., Ltd., Beijing Hotgen Biotechn Co., Ltd, Humasis, Accuquik™ Test Kits, CTK Biotech, Inc, INTEC, XIAMEN BOSON BIOTECH CO., LTD, AccuBioTech Co., Ltd., Bio-Rad Laboratories, Inc., Accuquik Test Kits, OPKO Health, Inc., bioMérieux SA, Beckman Coulter, Inc., Abbott, Siemens Healthcare, DiaSorin , Roche, Mediwatch (LABORIE), BodiTech, Bristol-Myers Squibb Company, GE Healthcare, Endocare , GlaxoSmithKline, Anixa Biosciences, Ortho Clinical , Fujirebio, Pharmacia Delfia

A crucial tumor marker for prostate cancer, prostate specific antigen (PSA), is a type of protein that is only released by certain cells. Although it is not a chemical specific to the prostate, its increased presence in blood serum is used to identify males with prostate cancer. A digital rectal exam (DRE) and PSA tests are used to check for prostate cancer in asymptomatic men. Clinicians and healthcare professionals now, frequently use PSA screening to look for potential prostate cancer cases to help them understand the nature of the issue.

Both healthy and cancerous cells of the prostate gland generate the PSA protein, which is exclusive to the prostate. A blood sample is sent to a lab for analysis as part of the PSA test, which gauges the level of PSA in the body. PSA levels in blood are often measured in nanograms (ng/mL).

Some organizations do advise starting PSA testing at age 40 or 45 for men who have a higher chance of developing prostate cancer. Males of color, those with BRCA2 germline variations (and, to a lesser extent, BRCA1 variants), and males whose father or brother had prostate cancer are among those at risk.

Overall, the increasing adoption of latest technologies and new product launches such as Compared to the presently utilized prostate-specific antigen (PSA) blood test, the prostate screening EpiSwitch (PSE) blood test is more than 90 percent accurate. this factors will boost the market in the coming years.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Prostate-Specific Antigen (PSA) Testing Market from 2018 to 2022 Vs Market Outlook for 2023 to 2033

Sales of the prostate-specific antigen (PSA) testing market grew at a CAGR of 9.9% between 2018 and 2022. Prostate-specific antigen (PSA) testing market contributes 3.4% revenue share to the cancer diagnostics market valued at US$ 166.2 Billion in 2022.

In order to monitor the progression of prostate cancer in men who had already received a diagnosis, the FDA originally authorized the PSA test in 1986. Patients with prostate cancer usually have increased PSA levels in their blood. In year 1994, the FDA approved the combination of PSA test with DRE to aid in the diagnosis of prostate cancer.

As more information about the advantages and disadvantages of prostate cancer screening became available starting about 2008, a number of professional medical organizations started to issue warnings against the PSA test's widespread use in population screening. The majority of organizations advise those who are thinking about PSA screening to first go over the advantages and disadvantages with their doctors.

Prostate explicit antigen testing market is driving ahead a result of expansion in geriatric population. Additionally, the growth of the prostate specific antigen market is influenced by technological advancements in prostate cancer testing and treatment, as well as a number of reimbursement policies for prostate cancer treatment in both developed and developing countries.

Creating awareness about diseases is an essential aspect of early detection and screening. If the public has a general understanding of diseases and symptoms, action plans can be better implemented. On the other hand, if there is a lack of awareness, it stops people from taking preventive measures or availing treatments.

Considering this, FMI expects the prostate-specific antigen (PSA) testing market to grow at a CAGR of 12.0% through the forecasted years.

What are the Key Opportunities for Key Players in the (PSA) Testing Market?

The rising prevalence of prostate cancer in men, particularly among those over 50, is driving the global market for prostate-specific specific antigen testing. After treatment for prostate cancer, PSA levels must also be checked on a regular basis.

  • As per World Health Organization (WHO), 2022 statistics, there are currently 1.41 million people suffering from prostate cancer as of date globally.

New item dispatches and new technological advancements are open doors for development in the market.

  • For example, USA FDA approved a radioembolization therapy offered by Boston Scientific Inc., using TheraSphere consisting of glass microspheres with radioactive Yttrium-90 (Y-90). The therapy allows for personalized treatment options.

A few reimbursement strategies in different created and creating locales cover yearly public service announcement testing among men with age at least 50. Besides, public service announcement testing being incorporated as a piece of the yearly wellbeing inclusion in created countries like USA is supposed to set out promising open doors for market players. These factors are expected to provide growth opportunities to key players in the market over the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors Could Possibly Restrain the Growth of Prostate-Specific Antigen (PSA) Testing Market?

Prostate explicit antigen testing market need to confront a few difficult circumstances due to the misleading positive or bogus adverse consequences of public service announcement test. Additionally, activities like public service announcement screening had a great deal of secondary effects, for example, troubles in progression of pee, consequences for working of entrails, erectile brokenness and successive torments alongside bogus outcomes; subsequently blocking the development of prostate explicit antigen testing market.

Higher improvement in the innovation resulting in most streamlined and exact outcomes in the tests like prostate wellbeing file (phi) can lessen the development in public service announcement testing market except if there is an adjustment of how the tests are dealt with.

Over determination of clinically immaterial prostate malignant growth, combined with exaggeration of the outcomes is a significant hindrance in the reception of public service announcement testing.

These factors are expected to hamper revenue growth of the prostate-specific antigen (PSA) testing market over the forecast period.

Country-wise Insights

What Makes the USA the Dominating Country in the Prostate-Specific Antigen (PSA) Testing Market?

In United States, prostate cancer is the most common malignancy among men, except from skin cancer.

  • In the US, 288,300 men will likely be diagnosed with prostate cancer in 2023. There are projected to be 1,414,259 new cases of prostate cancer worldwide in 2020. It ranks as the fourth most common cancer in the world according to diagnostic rates, provided by WHO in 2022.
  • Between 2007 and 2014, there was a considerable decline in the incidence of prostate cancer since screening guidelines at the time resulted in less PSA testing. While incidence rates for prostate cancer in its late stages have grown by 5% yearly since 2014, overall incidence rates have only increased by about 3% since 2014.

During the projected period, the market for prostate-specific antigen (PSA) testing in the United States is anticipated to grow at a CAGR of 10.2%.

Due to the high prevalence of prostate cancer diagnostic methods will be in demand for prostate-specific antigen testing, which will drive the expansion of the market.

Why is Germany considered to be a Lucrative Segment for Prostate-Specific Antigen (PSA) Testing Market in Europe?

Germany dominated the European market for prostate-specific antigen (PSA) testing market and accounted for around 29.8% of the market share in 2022.

Recent investigations by University of East Anglia’, Europe, have shown that the prostate screening blood test EpiSwitch (PSE) is more accurate than the currently used PSA blood test by more than 90%. The new test provides an accurate and speedy cancer screening diagnosis, according to the study team. The PSE test offers a rapid, minimally invasive prostate cancer detection and has exceptional effectiveness when used to screen a population at risk.

Over the years, due to growing number of research activities to develop new testing options in prostate cancer testing, Germany market for PSA testing will grow.

The safe and successful use PSA testing in Germany will influence other European countries to also opt for this method, ultimately expanding the overall market.

What Makes China an Emerging Market for East Asia Prostate-Specific Antigen (PSA) Testing Market?

China is projected to be the most attractive market in the East Asia prostate-specific antigen (PSA) testing market and is expected to grow over a significant CAGR of 11.2%.

The growing public and professional awareness of the condition is one of the main factors influencing the growth of the prostate-specific antigen (PSA) testing market in China.

  • For example, as per the Hong Kong awareness study, 2021, published in NCBI, only 5% of participants had undergone prostate cancer screening in the past, but more than 65% planned to do so in the future.
  • Prostate-specific antigen (PSA) testing market demand is rising as more individuals become aware of the test and are thus more likely to adapt to the testing procedure.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Why Immunoassay Is Largely Adopted for Prostate-Specific Antigen (PSA) Testing?

The Immunoassay segment held the major chunk of about 56.8% in global market by the end of 2022.

Many of infectious diseases require rapid diagnosis that’s where prostate-specific antigen (PSA) testing market diagnostics plays a significant role.

Prostate-specific antigen (PSA) testing involves testing type such as immunoassays, ELISA kits, lateral flow assays, chemiluminescent immunoassays (CLIAs), radioimmunoassay, point-of-care testing kits, cassette/cards, strips. However, Immunoassay testing is preferred over POCT because immunoassays have more specificity and more reliable results.

Overall, PSA test is used for detection of prostate-specific antigen due to their high specificity.

Which Sample Type of Prostate-Specific Antigen (PSA) Testing Market Dominates the Global Market in 2022?

Whole blood segment accounted for revenue share of 52.4% in the global market at the end of 2022.

Complete blood count tests are frequently advised by doctors to track patient’s health. This blood test can be used in cancer therapy to aid in the diagnosis of a malignancy or to track how the disease or its treatment is impacting the patient's body.

Overall, whole blood offers a convenient sample type for prostate-specific antigen (PSA) testing market treating products, making it the most significant sample for this segment.

Which End User of Prostate-Specific Antigen (PSA) Testing Market Dominates the Global Market in 2022?

Hospitals segment accounted for revenue share of 44.1% in the global market at the end of 2022.

Hospitals have availability of testing kits and hospitals are main source of blood sample withdrawing channel for prostate-specific antigen (PSA) testing.

Overall, hospitals offers a convenient testing options for prostate-specific antigen (PSA) testing, making it the dominant end user for this segment.

Competitive Landscape

The prostate-specific antigen (PSA) testing market's major companies are concentrating on diversifying their product offerings to boost their market share and establish a presence in developing nations. Pricing strategies, market strategies, technology improvements, regulatory compliance, and acquisition and distribution agreements with other firms to extend their company are the main tactics used by manufacturers to acquire a competitive advantage in the market.

For instance:

  • In Jun 2021, GE Healthcare bought new molecular imaging goods and solutions at the Society of nuclear medicine and molecular imaging (SNMMI) summer meeting.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Prostate-specific Antigen (PSA) Testing market space, which are available in the full report

Scope of the Prostate-Specific Antigen (PSA) Testing Market Report

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Market Analysis USD Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA)
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries
Key Segments Covered Test Type, Sample Type, End User, Region
Key Companies Profiled
  • Xiamen Biotime Biotechnology Co., Ltd.
  • HWTAi,
  • OptiBio Co., Ltd
  • Jiangsu MicroDiag Biomedicine Technology Co., Ltd.
  • Beijing Hotgen Biotechn Co., Ltd
  • Humasis, Accuquik™ Test Kits
  • CTK Biotech, Inc.
  • INTEC
  • XIAMEN BOSON BIOTECH CO., LTD
  • AccuBioTech Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Accuquik Test Kits
  • OPKO Health, Inc.
  • bioMérieux SA
  • Beckman Coulter, Inc.
  • Abbott
  • Siemens Healthcare
  • DiaSorin
  • F. Hoffmann-La Roche Ltd
  • Mediwatch (LABORIE)
  • BodiTech
  • Bristol-Myers Squibb Company
  • GE Healthcare
  • Endocare
  • GlaxoSmithKline
  • Anixa Biosciences
  • Ortho Clinical
  • Fujirebio
  • Pharmacia Delfia
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segments Covered in Prostate-Specific Antigen (PSA) Testing Market

By Test Type:

  • Immunoassays
    • ELISA Kits
    • Lateral Flow Assays
    • Chemiluminescent Immunoassays (CLIA)
    • Radioimmunoassay
  • Point-of-Care Testing Kits
    • Cassette/Cards
    • Strips

By Sample Type:

  • Whole Blood
  • Serum
  • Plasma

By End User:

  • Hospitals
  • Diagnostics laboratories
  • Specialty Clinics
  • Research Institutes
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

What Factors are Influencing the Growth of the PSA Testing Market?

Aging populations and prostate cancer awareness influencing the market growth.

How Does the Market Vary Across Different Regions?

Asia Pacific is expanding quickly because of better healthcare infrastructure.

Which Segment Leads the PSA Testing Market?

Laboratory-based PSA testing segment occupies a dominant position in the market.

What are Some Key Insights About the PSA Testing Market?

The rising incidence of prostate cancer and improvements in diagnostic technology.

Which Region is Transforming the PSA Testing Market?

The North America has seen significant adoption of PSA testing on a global scale.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Key Success Factors

    4.1. Product Adoption Analysis

    4.2. Regulatory Scenario

    4.3. Reimbursement Landscape

    4.4. PESTLE Analysis

    4.5. Porter’s Analysis

    4.6. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure

        5.1.3. Global IVD Market Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Top Companies Historical Growth

        5.2.2. Increasing Treatment Seeking Rate

        5.2.3. New Test Type Launches/Approvals

        5.2.4. Increasing Incidence of Prostate Cancer

        5.2.5. Government Initiatives to Combat Prostate Cancer

        5.2.6. Companies Increasingly Spending on R&D and Focus on Innovation

        5.2.7. Collaborations and Agreements between Manufacturers

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Test Type

        6.1.2. By Sample Type

        6.1.3. By End User

    6.2. 2022 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033

    7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022

    7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033

        8.3.1. Immunoassays

            8.3.1.1. ELISA kits

            8.3.1.2. Lateral flow assays

            8.3.1.3. Chemiluminescent immunoassays (CLIAs)

            8.3.1.4. Radioimmunoassay

        8.3.2. Kits

            8.3.2.1. Cassette/Cards

            8.3.2.2. Strips

    8.4. Market Attractiveness Analysis by Test Type

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis by Sample Type, 2018 to 2022

    9.3. Current and Future Market Size (US$ Million) and Forecast by Sample Type, 2023 to 2033

        9.3.1. Whole Blood

        9.3.2. Serum

        9.3.3. Plasma

    9.4. Market Attractiveness Analysis by Sample Type

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) By End User, 2018 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        10.3.1. Hospitals

        10.3.2. Diagnostics laboratories

        10.3.3. Specialty Clinics

        10.3.4. Research Institutes

        10.3.5. Others

    10.4. Market Attractiveness Analysis by End User

11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. South Asia

        11.3.5. East Asia

        11.3.6. Oceania

        11.3.7. Middle East & Africa

    11.4. Market Attractiveness Analysis By Country

12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. USA   

            12.3.1.2. Canada

        12.3.2. By Test Type

        12.3.3. By Sample Type

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Test Type

        12.4.3. By Sample Type

        12.4.4. By End User

    12.5. Market Trends

    12.6. Key Market Participant - Intensity Mapping

    12.7. Drivers & Restraints Impact Analysis

    12.8. Country-wise Analysis

        12.8.1. USA Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Test Type

                12.8.1.2.2. By Sample Type

                12.8.1.2.3. By End User

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Test Type

                12.8.2.2.2. By Sample Type

                12.8.2.2.3. By End User

13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Test Type

        13.3.3. By Sample Type

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Test Type

        13.4.3. By Sample Type

        13.4.4. By End User

    13.5. Market Trends

    13.6. Key Market Participant - Intensity Mapping

    13.7. Drivers & Restraints Impact Analysis

    13.8. Country-wise Analysis

        13.8.1. Brazil Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Test Type

                13.8.1.2.2. By Sample Type

                13.8.1.2.3. By End User

        13.8.2. Mexico Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Test Type

                13.8.2.2.2. By Sample Type

                13.8.2.2.3. By End User

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Test Type

                13.8.3.2.2. By Sample Type

                13.8.3.2.3. By End User

14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. UK

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Test Type

        14.3.3. By Sample Type

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Test Type

        14.4.3. By Sample Type

        14.4.4. By End User

    14.5. Market Trends

    14.6. Key Market Participant - Intensity Mapping

    14.7. Drivers & Restraints Impact Analysis

    14.8. Country-wise Analysis

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Test Type

                14.8.1.2.2. By Sample Type

                14.8.1.2.3. By End User

        14.8.2. Italy Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Test Type

                14.8.2.2.2. By Sample Type

                14.8.2.2.3. By End User

        14.8.3. France Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Test Type

                14.8.3.2.2. By Sample Type

                14.8.3.2.3. By End User

        14.8.4. UK Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Test Type

                14.8.4.2.2. By Sample Type

                14.8.4.2.3. By End User

        14.8.5. Spain Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Test Type

                14.8.5.2.2. By Sample Type

                14.8.5.2.3. By End User

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Test Type

                14.8.6.2.2. By Sample Type

                14.8.6.2.3. By End User

        14.8.7. Russia Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Test Type

                14.8.7.2.2. By Sample Type

                14.8.7.2.3. By End User

15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Malaysia

            15.3.1.4. Thailand

            15.3.1.5. Rest of South Asia

        15.3.2. By Test Type

        15.3.3. By Sample Type

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Test Type

        15.4.3. By Sample Type

        15.4.4. By End User

    15.5. Market Trends

    15.6. Key Market Participant - Intensity Mapping

    15.7. Drivers & Restraints Impact Analysis

    15.8. Country-wise Analysis

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Test Type

                15.8.1.2.2. By Sample Type

                15.8.1.2.3. By End User

        15.8.2. Indonesia Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Test Type

                15.8.2.2.2. By Sample Type

                15.8.2.2.3. By End User

        15.8.3. Malaysia Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Test Type

                15.8.3.2.2. By Sample Type

                15.8.3.2.3. By End User

        15.8.4. Thailand Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Test Type

                15.8.4.2.2. By Sample Type

                15.8.4.2.3. By End User

16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Test Type

        16.3.3. By Sample Type

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Test Type

        16.4.3. By Sample Type

        16.4.4. By End User

    16.5. Market Trends

    16.6. Key Market Participant - Intensity Mapping

    16.7. Drivers & Restraints Impact Analysis

    16.8. Country-wise Analysis

        16.8.1. China Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Test Type

                16.8.1.2.2. By Sample Type

                16.8.1.2.3. By End User

        16.8.2. Japan Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Test Type

                16.8.2.2.2. By Sample Type

                16.8.2.2.3. By End User

        16.8.3. South Korea Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Test Type

                16.8.3.2.2. By Sample Type

                16.8.3.2.3. By End User

17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Test Type

        17.3.3. By Sample Type

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Test Type

        17.4.3. By Sample Type

        17.4.4. By End User

    17.5. Market Trends

    17.6. Key Market Participant - Intensity Mapping

    17.7. Drivers & Restraints Impact Analysis

    17.8. Country-wise Analysis

        17.8.1. Australia Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Test Type

                17.8.1.2.2. By Sample Type

                17.8.1.2.3. By End User

        17.8.2. New Zealand Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Test Type

                17.8.2.2.2. By Sample Type

                17.8.2.2.3. By End User

18. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022

    18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. GCC Country

            18.3.1.2. Turkey

            18.3.1.3. South Africa

            18.3.1.4. North Africa

            18.3.1.5. Rest of MEA

        18.3.2. By Test Type

        18.3.3. By Sample Type

        18.3.4. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Test Type

        18.4.3. By Sample Type

        18.4.4. By End User

    18.5. Market Trends

    18.6. Key Market Participant - Intensity Mapping

    18.7. Drivers & Restraints Impact Analysis

    18.8. Country-wise Analysis

        18.8.1. GCC Country Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Test Type

                18.8.1.2.2. By Sample Type

                18.8.1.2.3. By End User

        18.8.2. Türkiye Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Test Type

                18.8.2.2.2. By Sample Type

                18.8.2.2.3. By End User

        18.8.3. South Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Test Type

                18.8.3.2.2. By Sample Type

                18.8.3.2.3. By End User

        18.8.4. North South Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Test Type

                18.8.4.2.2. By Sample Type

                18.8.4.2.3. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players (%)

    19.3. Market Concentration

    19.4. Market Presence Analysis

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Key Development Analysis

    20.3. Branding and Promotional Strategies, By Key Players

    20.4. Competition Deep Dive

        20.4.1. Xiamen Biotime Biotechnology Co. Ltd.

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. Key Financials

            20.4.1.4. SWOT Analysis

            20.4.1.5. Key Developments

            20.4.1.6. Sales Footprint

            20.4.1.7. Strategy Overview

                20.4.1.7.1. Marketing Strategy

                20.4.1.7.2. Product Strategy

                20.4.1.7.3. Channel Strategy

        20.4.2. HWTAi,

            20.4.2.1. Overview

            20.4.2.2. Product Portfolio

            20.4.2.3. Key Financials

            20.4.2.4. SWOT Analysis

            20.4.2.5. Key Developments

            20.4.2.6. Sales Footprint

            20.4.2.7. Strategy Overview

                20.4.2.7.1. Marketing Strategy

                20.4.2.7.2. Product Strategy

                20.4.2.7.3. Channel Strategy

        20.4.3. OptiBio Co., Ltd

            20.4.3.1. Overview

            20.4.3.2. Product Portfolio

            20.4.3.3. Key Financials

            20.4.3.4. SWOT Analysis

            20.4.3.5. Key Developments

            20.4.3.6. Sales Footprint

            20.4.3.7. Strategy Overview

                20.4.3.7.1. Marketing Strategy

                20.4.3.7.2. Product Strategy

                20.4.3.7.3. Channel Strategy

        20.4.4. Jiangsu MicroDiag Biomedicine Technology Co., Ltd.

            20.4.4.1. Overview

            20.4.4.2. Product Portfolio

            20.4.4.3. Key Financials

            20.4.4.4. SWOT Analysis

            20.4.4.5. Key Developments

            20.4.4.6. Sales Footprint

            20.4.4.7. Strategy Overview

                20.4.4.7.1. Marketing Strategy

                20.4.4.7.2. Product Strategy

                20.4.4.7.3. Channel Strategy

        20.4.5. Beijing Hotgen Biotechn Co., Ltd

            20.4.5.1. Overview

            20.4.5.2. Product Portfolio

            20.4.5.3. Key Financials

            20.4.5.4. SWOT Analysis

            20.4.5.5. Key Developments

            20.4.5.6. Sales Footprint

            20.4.5.7. Strategy Overview

                20.4.5.7.1. Marketing Strategy

                20.4.5.7.2. Product Strategy

                20.4.5.7.3. Channel Strategy

        20.4.6. Humasis, Accuquik™ Test Kits

            20.4.6.1. Overview

            20.4.6.2. Product Portfolio

            20.4.6.3. Key Financials

            20.4.6.4. SWOT Analysis

            20.4.6.5. Key Developments

            20.4.6.6. Sales Footprint

            20.4.6.7. Strategy Overview

                20.4.6.7.1. Marketing Strategy

                20.4.6.7.2. Product Strategy

                20.4.6.7.3. Channel Strategy

        20.4.7. CTK Biotech, Inc

            20.4.7.1. Overview

            20.4.7.2. Product Portfolio

            20.4.7.3. Key Financials

            20.4.7.4. SWOT Analysis

            20.4.7.5. Key Developments

            20.4.7.6. Sales Footprint

            20.4.7.7. Strategy Overview

                20.4.7.7.1. Marketing Strategy

                20.4.7.7.2. Product Strategy

                20.4.7.7.3. Channel Strategy

        20.4.8. INTEC

            20.4.8.1. Overview

            20.4.8.2. Product Portfolio

            20.4.8.3. Key Financials

            20.4.8.4. SWOT Analysis

            20.4.8.5. Key Developments

            20.4.8.6. Sales Footprint

            20.4.8.7. Strategy Overview

                20.4.8.7.1. Marketing Strategy

                20.4.8.7.2. Product Strategy

                20.4.8.7.3. Channel Strategy

        20.4.9. XIAMEN BOSON BIOTECH CO., LTD

            20.4.9.1. Overview

            20.4.9.2. Product Portfolio

            20.4.9.3. Key Financials

            20.4.9.4. SWOT Analysis

            20.4.9.5. Key Developments

            20.4.9.6. Sales Footprint

            20.4.9.7. Strategy Overview

                20.4.9.7.1. Marketing Strategy

                20.4.9.7.2. Product Strategy

                20.4.9.7.3. Channel Strategy

        20.4.10. AccuBioTech Co., Ltd.

            20.4.10.1. Overview

            20.4.10.2. Product Portfolio

            20.4.10.3. Key Financials

            20.4.10.4. SWOT Analysis

            20.4.10.5. Key Developments

            20.4.10.6. Sales Footprint

            20.4.10.7. Strategy Overview

                20.4.10.7.1. Marketing Strategy

                20.4.10.7.2. Product Strategy

                20.4.10.7.3. Channel Strategy

        20.4.11. Bio-Rad Laboratories, Inc.

            20.4.11.1. Overview

            20.4.11.2. Product Portfolio

            20.4.11.3. Key Financials

            20.4.11.4. SWOT Analysis

            20.4.11.5. Key Developments

            20.4.11.6. Sales Footprint

            20.4.11.7. Strategy Overview

                20.4.11.7.1. Marketing Strategy

                20.4.11.7.2. Product Strategy

                20.4.11.7.3. Channel Strategy

        20.4.12. Accuquik Test Kits

            20.4.12.1. Overview

            20.4.12.2. Product Portfolio

            20.4.12.3. Key Financials

            20.4.12.4. SWOT Analysis

            20.4.12.5. Key Developments

            20.4.12.6. Sales Footprint

            20.4.12.7. Strategy Overview

                20.4.12.7.1. Marketing Strategy

                20.4.12.7.2. Product Strategy

                20.4.12.7.3. Channel Strategy

        20.4.13. OPKO Health, Inc.

            20.4.13.1. Overview

            20.4.13.2. Product Portfolio

            20.4.13.3. Key Financials

            20.4.13.4. SWOT Analysis

            20.4.13.5. Key Developments

            20.4.13.6. Sales Footprint

            20.4.13.7. Strategy Overview

                20.4.13.7.1. Marketing Strategy

                20.4.13.7.2. Product Strategy

                20.4.13.7.3. Channel Strategy

        20.4.14. bioMérieux SA

            20.4.14.1. Overview

            20.4.14.2. Product Portfolio

            20.4.14.3. Key Financials

            20.4.14.4. SWOT Analysis

            20.4.14.5. Key Developments

            20.4.14.6. Sales Footprint

            20.4.14.7. Strategy Overview

                20.4.14.7.1. Marketing Strategy

                20.4.14.7.2. Product Strategy

                20.4.14.7.3. Channel Strategy

        20.4.15. Beckman Coulter, Inc

            20.4.15.1. Overview

            20.4.15.2. Product Portfolio

            20.4.15.3. Key Financials

            20.4.15.4. SWOT Analysis

            20.4.15.5. Key Developments

            20.4.15.6. Sales Footprint

            20.4.15.7. Strategy Overview

                20.4.15.7.1. Marketing Strategy

                20.4.15.7.2. Product Strategy

                20.4.15.7.3. Channel Strategy

        20.4.16. Abbott

            20.4.16.1. Overview

            20.4.16.2. Product Portfolio

            20.4.16.3. Key Financials

            20.4.16.4. SWOT Analysis

            20.4.16.5. Key Developments

            20.4.16.6. Sales Footprint

            20.4.16.7. Strategy Overview

                20.4.16.7.1. Marketing Strategy

                20.4.16.7.2. Product Strategy

                20.4.16.7.3. Channel Strategy

        20.4.17. Siemens Healthcare

            20.4.17.1. Overview

            20.4.17.2. Product Portfolio

            20.4.17.3. Key Financials

            20.4.17.4. SWOT Analysis

            20.4.17.5. Key Developments

            20.4.17.6. Sales Footprint

            20.4.17.7. Strategy Overview

                20.4.17.7.1. Marketing Strategy

                20.4.17.7.2. Product Strategy

                20.4.17.7.3. Channel Strategy

        20.4.18. DiaSorin

            20.4.18.1. Overview

            20.4.18.2. Product Portfolio

            20.4.18.3. Key Financials

            20.4.18.4. SWOT Analysis

            20.4.18.5. Key Developments

            20.4.18.6. Sales Footprint

            20.4.18.7. Strategy Overview

                20.4.18.7.1. Marketing Strategy

                20.4.18.7.2. Product Strategy

                20.4.18.7.3. Channel Strategy

        20.4.19. F. Hoffmann-La Roche Ltd

            20.4.19.1. Overview

            20.4.19.2. Product Portfolio

            20.4.19.3. Key Financials

            20.4.19.4. SWOT Analysis

            20.4.19.5. Key Developments

            20.4.19.6. Sales Footprint

            20.4.19.7. Strategy Overview

                20.4.19.7.1. Marketing Strategy

                20.4.19.7.2. Product Strategy

                20.4.19.7.3. Channel Strategy

        20.4.20. Mediwatch (LABORIE)

            20.4.20.1. Overview

            20.4.20.2. Product Portfolio

            20.4.20.3. Key Financials

            20.4.20.4. SWOT Analysis

            20.4.20.5. Key Developments

            20.4.20.6. Sales Footprint

            20.4.20.7. Strategy Overview

                20.4.20.7.1. Marketing Strategy

                20.4.20.7.2. Product Strategy

                20.4.20.7.3. Channel Strategy

        20.4.21. BodiTech

            20.4.21.1. Overview

            20.4.21.2. Product Portfolio

            20.4.21.3. Key Financials

            20.4.21.4. SWOT Analysis

            20.4.21.5. Key Developments

            20.4.21.6. Sales Footprint

            20.4.21.7. Strategy Overview

                20.4.21.7.1. Marketing Strategy

                20.4.21.7.2. Product Strategy

                20.4.21.7.3. Channel Strategy

        20.4.22. Bristol-Myers Squibb Company

            20.4.22.1. Overview

            20.4.22.2. Product Portfolio

            20.4.22.3. Key Financials

            20.4.22.4. SWOT Analysis

            20.4.22.5. Key Developments

            20.4.22.6. Sales Footprint

            20.4.22.7. Strategy Overview

                20.4.22.7.1. Marketing Strategy

                20.4.22.7.2. Product Strategy

                20.4.22.7.3. Channel Strategy

        20.4.23. GE Healthcare

            20.4.23.1. Overview

            20.4.23.2. Product Portfolio

            20.4.23.3. Key Financials

            20.4.23.4. SWOT Analysis

            20.4.23.5. Key Developments

            20.4.23.6. Sales Footprint

            20.4.23.7. Strategy Overview

                20.4.23.7.1. Marketing Strategy

                20.4.23.7.2. Product Strategy

                20.4.23.7.3. Channel Strategy

        20.4.24. Endocare

            20.4.24.1. Overview

            20.4.24.2. Product Portfolio

            20.4.24.3. Key Financials

            20.4.24.4. SWOT Analysis

            20.4.24.5. Key Developments

            20.4.24.6. Sales Footprint

            20.4.24.7. Strategy Overview

                20.4.24.7.1. Marketing Strategy

                20.4.24.7.2. Product Strategy

                20.4.24.7.3. Channel Strategy

        20.4.25. GlaxoSmithKline

            20.4.25.1. Overview

            20.4.25.2. Product Portfolio

            20.4.25.3. Key Financials

            20.4.25.4. SWOT Analysis

            20.4.25.5. Key Developments

            20.4.25.6. Sales Footprint

            20.4.25.7. Strategy Overview

                20.4.25.7.1. Marketing Strategy

                20.4.25.7.2. Product Strategy

                20.4.25.7.3. Channel Strategy

        20.4.26. Anixa Biosciences

            20.4.26.1. Overview

            20.4.26.2. Product Portfolio

            20.4.26.3. Key Financials

            20.4.26.4. SWOT Analysis

            20.4.26.5. Key Developments

            20.4.26.6. Sales Footprint

            20.4.26.7. Strategy Overview

                20.4.26.7.1. Marketing Strategy

                20.4.26.7.2. Product Strategy

                20.4.26.7.3. Channel Strategy

        20.4.27. Ortho Clinical

            20.4.27.1. Overview

            20.4.27.2. Product Portfolio

            20.4.27.3. Key Financials

            20.4.27.4. SWOT Analysis

            20.4.27.5. Key Developments

            20.4.27.6. Sales Footprint

            20.4.27.7. Strategy Overview

                20.4.27.7.1. Marketing Strategy

                20.4.27.7.2. Product Strategy

                20.4.27.7.3. Channel Strategy

        20.4.28. Fujirebio

            20.4.28.1. Overview

            20.4.28.2. Product Portfolio

            20.4.28.3. Key Financials

            20.4.28.4. SWOT Analysis

            20.4.28.5. Key Developments

            20.4.28.6. Sales Footprint

            20.4.28.7. Strategy Overview

                20.4.28.7.1. Marketing Strategy

                20.4.28.7.2. Product Strategy

                20.4.28.7.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Explore Healthcare Insights

View Reports

Prostate-Specific Antigen Testing Market